2016
DOI: 10.1080/14737175.2016.1197119
|View full text |Cite
|
Sign up to set email alerts
|

Repetitive transcranial magnetic stimulation for the treatment of refractory epilepsy

Abstract: This manuscript provides an overview of the performed studies, retrieved from a PubMed search, and a critical appraisal of their results. A number of conclusions are drawn and potential optimization strategies are discussed. Expert commentary: Although the therapeutic efficacy of rTMS in refractory epilepsy has not yet been established, the non-invasiveness of the technique warrants further investigation of rTMS as a treatment for epilepsy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0
1

Year Published

2016
2016
2025
2025

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 22 publications
(15 citation statements)
references
References 90 publications
0
14
0
1
Order By: Relevance
“…A better understanding of the stimulation parameters which mediate input-specific synaptic changes, together with molecular studies on how rTMS modulates excitation/inhibition-balance, may help devising new therapeutic strategies using rTMS combined with pharmacological intervention. These studies could support for example, the development of more efficient rTMS-based therapies in post-stroke rehabilitation (Ziemann, 2005; Brodie et al, 2014; Smith and Stinear, 2016) or epilepsy (e.g., Carrette et al, 2016; Gersner et al, 2016), which already intend to target alterations in excitation/inhibition-balance. We hope rTMS-induced local disinhibition will be considered in future basic and clinical studies.…”
Section: Some Open Questions and Future Directionsmentioning
confidence: 98%
“…A better understanding of the stimulation parameters which mediate input-specific synaptic changes, together with molecular studies on how rTMS modulates excitation/inhibition-balance, may help devising new therapeutic strategies using rTMS combined with pharmacological intervention. These studies could support for example, the development of more efficient rTMS-based therapies in post-stroke rehabilitation (Ziemann, 2005; Brodie et al, 2014; Smith and Stinear, 2016) or epilepsy (e.g., Carrette et al, 2016; Gersner et al, 2016), which already intend to target alterations in excitation/inhibition-balance. We hope rTMS-induced local disinhibition will be considered in future basic and clinical studies.…”
Section: Some Open Questions and Future Directionsmentioning
confidence: 98%
“…Application of cTBS to M1 and other brain areas has been used to measure abnormalities in cortical plasticity and to assess therapeutic responses to interventions aimed at restoring normal cortical plasticity in several neurological and psychiatric disorders, including Alzheimer’s disease (Freitas et al, 2011a), autism spectrum disorders and fragile X syndrome (Oberman et al, 2010, 2012, 2014, 2016), dementia (Cantone et al, 2014), epilepsy (Carrette et al, 2016), essential tremor (Chuang et al, 2014), hemispatial neglect (Cazzoli et al, 2012; Koch et al, 2012), major depression (Li et al, 2014), multiple sclerosis (Mori et al, 2013), obsessive-compulsive disorders (Wu et al, 2010; Suppa et al, 2014), Parkinson’s disease (Koch et al, 2009), schizophrenia (Poulet et al, 2009; Eberle et al, 2010; McClintock et al, 2011), stroke (Ackerley et al, 2010; Hsu et al, 2012; Di Lazzaro et al, 2013, 2016), tinnitus (Forogh et al, 2014), and Tourette syndrome (Suppa et al, 2014). …”
Section: Introductionmentioning
confidence: 99%
“…In the study of Tergau and colleagues, actively treated patients experienced a significant approximately 40% reduction in seizure frequency compared with baseline, but this difference was not significant when compared with the placebo group. Reported adverse events include headache, dizziness, and tinnitus, but in none of the RCTs, these occurred at statistically significantly higher rates in the active treatment group [50][51][52]. In conclusion, although there is some evidence that rTMS is safe and well-tolerated;, there is insufficient evidence that proves its efficacy in reducing seizure frequency in patients with refractory epilepsy.…”
Section: Traditional and Novel Antiepileptic Devicesmentioning
confidence: 84%